Drugs / Gene-Corrected Macrophages
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05761899 | Jun 2023 → Sep 2026 overdue | hereditary pulmonary alveolar proteinosis | Children's Hospital Medical Center, Cincinnati | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Gene-Corrected Macrophages | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05761899 ↗ |
| Action | Restore | “uses a novel approach to restore AM function” NCT05761899 ↗ |
| Modality | Cell therapy | “new type of cell transplantation therapy” NCT05761899 ↗ |
| Route | Other | “by bronchoscopic instillation into individual lung segments” NCT05761899 ↗ |
| Target | CSF2RA | “CSF2RA gene-corrected macrophages” NCT05761899 ↗ |